E+P continues to have a comparable safety profile to pembrolizumab alone other than injection site reactions as expected with ...

CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on PDS Biotechnology (PDSB – Research Report). The ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

Bristol Myers Squibb today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients ...

GV20 Therapeutics, a clinical-stage AI-based next generation biotherapeutics company, today announced presentation of clinical results from its Phase 1/2 study of GV20-0251 at the European Society for ...

Just a few months prior to that deal Merck purchased Australian-based Viralytics for just under $400 million, giving them rights to develop and test Keytruda (pembrolizumab) with Viralytics ...

AT278 met all primary and secondary endpoints and it enables potential delivery of a highly concentrated, low volume injection for ... in combination with 200 mg pembrolizumab in the treatment ...

After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...